(0343–0371) SLE – Treatment Poster I

Saturday, November 12, 2022

1:00 PM – 3:00 PM Eastern Time

Location: Virtual Poster Hall

All of the relevant financial relationships listed for faculty have been mitigated.

Poster abstract session.

Presentations:

1:00 PM – 3:00 PM Eastern Time

Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Poster Presenter: Yann Nguyen, MD, PhD – AP-HP.Centre Université Paris Cité Hôpital Cochin
1:00 PM – 3:00 PM Eastern Time

Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Abstract Poster Presenter: Shivani Garg, MD, MS – University of Madison, School of Medicine and Public Health
1:00 PM – 3:00 PM Eastern Time

Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Abstract Poster Presenter: Alba Herrero-Morant, MD – Hospital Universitario Marqués de Valdecilla
1:00 PM – 3:00 PM Eastern Time

Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting
Abstract Poster Presenter: George Gennaoui, DO – The Toledo Clinic
1:00 PM – 3:00 PM Eastern Time

Real-World Effectiveness of Belimumab in Patients with SLE in the United States
Abstract Poster Presenter: Karen Worley, PhD, MS – GlaxoSmithKline, US Value, Evidence and Outcomes
1:00 PM – 3:00 PM Eastern Time

Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Abstract Poster Presenter: Shivani Garg, MD, MS – University of Madison, School of Medicine and Public Health
1:00 PM – 3:00 PM Eastern Time

Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
Abstract Poster Presenter: Emma Materne, MD – Massachusetts General Hospital
1:00 PM – 3:00 PM Eastern Time

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
Abstract Poster Presenter: Vicente Aldasoro Caceres, MD – Hospital Universitario de Navarra
1:00 PM – 3:00 PM Eastern Time

The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study
Abstract Poster Presenter: Yasuhiro Hasegawa, MD – Kitasato University
1:00 PM – 3:00 PM Eastern Time

The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
Abstract Poster Presenter: Maria Dall'Era, MD – UCSF
1:00 PM – 3:00 PM Eastern Time

Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
Abstract Poster Presenter: Cristian Alejandro Dimas Ramírez, BS – Universidad Nacional Autónoma de México
1:00 PM – 3:00 PM Eastern Time

Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Abstract Poster Presenter: Sandra Wu, PhD – AstraZeneca
1:00 PM – 3:00 PM Eastern Time

Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
Abstract Poster Presenter: Amit Saxena, MD – NYU School of Medicine
1:00 PM – 3:00 PM Eastern Time

Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Abstract Poster Presenter: Lucy Hodge, PhD, PharmD – Aurinia Pharmaceuticals
1:00 PM – 3:00 PM Eastern Time

Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
Abstract Poster Presenter: Raymond Federico, MS, MBA – Aurinia Pharmaceuticals, Inc.
1:00 PM – 3:00 PM Eastern Time

Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
Abstract Poster Presenter: Vanessa Birardi, PharmD – Aurinia Pharmaceuticals Inc
1:00 PM – 3:00 PM Eastern Time

Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
Abstract Poster Presenter: Eric Morand, MD, PhD – Monash University
1:00 PM – 3:00 PM Eastern Time

Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
Abstract Poster Presenter: Mark Lazarus, MD, PhD – AstraZeneca
1:00 PM – 3:00 PM Eastern Time

Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
Abstract Poster Presenter: Tina Baker, PhD – Astrazeneca
1:00 PM – 3:00 PM Eastern Time

The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
Abstract Poster Presenter: Hermine I. Brunner, MD, MSc, MBA – Cincinnati Children's Hospital Medical Center
1:00 PM – 3:00 PM Eastern Time

Centrally-Acting Angiotensin Converting Enzyme Inhibitor (cACEi) and Angiotensin Receptor Blocker (cARB) Use and Cognitive Dysfunction in Patients with Systemic Lupus
Abstract Poster Presenter: Chrisanna Dobrowolski, MD, MS – Icahn School of Medicine at Mount Sinai
1:00 PM – 3:00 PM Eastern Time

Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Abstract Poster Presenter: Richard Furie, MD – Northwell Health
1:00 PM – 3:00 PM Eastern Time

Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Abstract Poster Presenter: Victoria Werth, MD – University of Pennsylvania
1:00 PM – 3:00 PM Eastern Time

Phase II Trial of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia
Abstract Poster Presenter: John E. mckinnon, MD, MSc – MUSC
1:00 PM – 3:00 PM Eastern Time

Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
Abstract Poster Presenter: April Jorge, MD – Massachusetts General Hospital
1:00 PM – 3:00 PM Eastern Time

Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
Abstract Poster Presenter: Erik Cimé-Aké, MD – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
1:00 PM – 3:00 PM Eastern Time

WITHDRAWN
1:00 PM – 3:00 PM Eastern Time

Preliminary Findings from a Randomized Clinical Trial Show a Remotely Delivered Psychological Intervention May Be Beneficial to Youth with Childhood-Onset Lupus
Abstract Poster Presenter: Andrea M. Knight, MD – Hospital for Sick Children
1:00 PM – 3:00 PM Eastern Time

A Phase 2, Double-blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
Abstract Poster Presenter: Meggan Mackay, MD, MS – Feinstein Institutes for Medical Research